KR102466616B1 - A composition for anti-obesity, anti-dyslipidemia, anti-oxidation or anti-inflammation comprising extracts of heracleum dissectum - Google Patents
A composition for anti-obesity, anti-dyslipidemia, anti-oxidation or anti-inflammation comprising extracts of heracleum dissectum Download PDFInfo
- Publication number
- KR102466616B1 KR102466616B1 KR1020200078514A KR20200078514A KR102466616B1 KR 102466616 B1 KR102466616 B1 KR 102466616B1 KR 1020200078514 A KR1020200078514 A KR 1020200078514A KR 20200078514 A KR20200078514 A KR 20200078514A KR 102466616 B1 KR102466616 B1 KR 102466616B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- heungan
- dokhwal
- composition
- dyslipidemia
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 93
- 239000000284 extract Substances 0.000 title claims abstract description 69
- 208000032928 Dyslipidaemia Diseases 0.000 title claims abstract description 24
- 208000017170 Lipid metabolism disease Diseases 0.000 title claims abstract description 24
- 206010061218 Inflammation Diseases 0.000 title abstract description 16
- 230000003579 anti-obesity Effects 0.000 title abstract description 5
- 241000467447 Heracleum dissectum Species 0.000 title description 3
- 230000003064 anti-oxidating effect Effects 0.000 title description 2
- 239000004480 active ingredient Substances 0.000 claims abstract description 13
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 44
- 208000008589 Obesity Diseases 0.000 claims description 25
- 235000020824 obesity Nutrition 0.000 claims description 25
- 235000013305 food Nutrition 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 10
- 230000003405 preventing effect Effects 0.000 claims description 8
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 7
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 5
- 238000009825 accumulation Methods 0.000 claims description 5
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 230000006872 improvement Effects 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 abstract description 15
- 150000002632 lipids Chemical class 0.000 abstract description 15
- 239000003963 antioxidant agent Substances 0.000 abstract description 14
- 230000003078 antioxidant effect Effects 0.000 abstract description 13
- 239000008280 blood Substances 0.000 abstract description 13
- 210000004369 blood Anatomy 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 12
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 11
- 230000003647 oxidation Effects 0.000 abstract description 7
- 238000007254 oxidation reaction Methods 0.000 abstract description 7
- 230000037396 body weight Effects 0.000 abstract description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 46
- 238000009472 formulation Methods 0.000 description 23
- 235000012000 cholesterol Nutrition 0.000 description 21
- 239000003925 fat Substances 0.000 description 17
- 235000019197 fats Nutrition 0.000 description 14
- 235000006708 antioxidants Nutrition 0.000 description 13
- 238000000605 extraction Methods 0.000 description 13
- 201000010063 epididymitis Diseases 0.000 description 12
- 210000001789 adipocyte Anatomy 0.000 description 11
- -1 etc.) Chemical compound 0.000 description 11
- 235000009200 high fat diet Nutrition 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 239000006210 lotion Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 210000000577 adipose tissue Anatomy 0.000 description 8
- 239000006071 cream Substances 0.000 description 8
- 239000000469 ethanolic extract Substances 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 239000008187 granular material Substances 0.000 description 8
- 208000027866 inflammatory disease Diseases 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 7
- 238000007796 conventional method Methods 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 235000019577 caloric intake Nutrition 0.000 description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 229940058015 1,3-butylene glycol Drugs 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 238000009007 Diagnostic Kit Methods 0.000 description 3
- 108010018924 Heme Oxygenase-1 Proteins 0.000 description 3
- 102100028006 Heme oxygenase 1 Human genes 0.000 description 3
- 101000973778 Homo sapiens NAD(P)H dehydrogenase [quinone] 1 Proteins 0.000 description 3
- 102100022297 Integrin alpha-X Human genes 0.000 description 3
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 3
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 3
- 101710091439 Major capsid protein 1 Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102100022365 NAD(P)H dehydrogenase [quinone] 1 Human genes 0.000 description 3
- 235000002789 Panax ginseng Nutrition 0.000 description 3
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 3
- 102100038836 Superoxide dismutase [Cu-Zn] Human genes 0.000 description 3
- 102100032891 Superoxide dismutase [Mn], mitochondrial Human genes 0.000 description 3
- 230000035508 accumulation Effects 0.000 description 3
- 210000000593 adipose tissue white Anatomy 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 108010045815 superoxide dismutase 2 Proteins 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- ACFGRWJEQJVZTM-LEJBHHMKSA-L Magnesium L-ascorbic acid-2-phosphate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1O ACFGRWJEQJVZTM-LEJBHHMKSA-L 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000013538 functional additive Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000006372 lipid accumulation Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 239000006201 parenteral dosage form Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- BWSWZBCSFZAYOB-CABCVRRESA-N (2s,4r)-1-dodecanoyl-4-hydroxypyrrolidine-2-carboxylic acid Chemical compound CCCCCCCCCCCC(=O)N1C[C@H](O)C[C@H]1C(O)=O BWSWZBCSFZAYOB-CABCVRRESA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 101150106966 FOXO1 gene Proteins 0.000 description 1
- 101150057663 Foxa2 gene Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 101710082961 GATA-binding factor 2 Proteins 0.000 description 1
- 101001066288 Gallus gallus GATA-binding factor 3 Proteins 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 1
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 1
- 101100485095 Mus musculus Wnt10b gene Proteins 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 102100036467 Protein delta homolog 1 Human genes 0.000 description 1
- 101710119301 Protein delta homolog 1 Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000006045 Spondylarthropathies Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000021407 appetite control Nutrition 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 208000005963 oophoritis Diseases 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 201000005737 orchitis Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 239000006211 transdermal dosage form Substances 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Botany (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Polymers & Plastics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 개시물에는 흥안독활 추출물을 유효성분으로 포함하는 항비만, 항이상지질혈증, 항산화 또는/및 항염 조성물이 개시된다. 상기 조성물은 체중 감소, 혈중 지질 개선, 지질 산화 억제 또는/및 염증 억제 효과를 제공한다.The present disclosure discloses an anti-obesity, anti-dyslipidemia, antioxidant or/and anti-inflammatory composition comprising Heungan dokhwal extract as an active ingredient. The composition provides effects of reducing body weight, improving blood lipids, inhibiting lipid oxidation or/and inhibiting inflammation.
Description
본 개시물에는 흥안독활 추출물을 유효성분으로 포함하는 항비만, 항이상지질혈증, 항산화 또는/및 항염 조성물이 개시된다.The present disclosure discloses an anti-obesity, anti-dyslipidemia, antioxidant or/and anti-inflammatory composition comprising Heungan dokhwal extract as an active ingredient.
비만은 현대인의 만성질환 중 하나로 산업화와 소득 수준 향상에 따른 식습관 및 생활습관 변화로 전세계적으로 가장 심각한 건강 문제 중 하나로 대두되고 있으며, 1996년에는 세계보건기구 (WHO)에 의하여 질병으로 규정되었다. Obesity is one of the chronic diseases of modern people, emerging as one of the most serious health problems worldwide due to changes in eating habits and lifestyles due to industrialization and improved income levels, and was defined as a disease by the World Health Organization (WHO) in 1996.
과체중 및 비만은 혈압과 콜레스테롤 수치를 높여 심장 질환, 고혈압, 고지혈증, 당뇨, 관절염 등 각종 질환의 원인이 되기도 하고, 각종 성인병의 발병률을 증가시키고 있다. 또한, 과체중 및 비만은 성인뿐만 아니라 어린이나 청소년들에서도 동맥경화, 고혈압, 고지혈증, 심장 질환 등 각종 성인병의 발병률을 증가시키는 한 요인이 되고 있다.Overweight and obesity increase blood pressure and cholesterol levels, causing various diseases such as heart disease, hypertension, hyperlipidemia, diabetes, and arthritis, and increasing the incidence of various adult diseases. In addition, overweight and obesity are one of the factors that increase the incidence of various adult diseases such as arteriosclerosis, hypertension, hyperlipidemia, and heart disease not only in adults but also in children and adolescents.
이와 같이, 비만은 전세계적인 질병으로 각종 질환의 원인이 되기도 하는 심각한 질병이지만 쉽게 치료할 수 없는 질병이다. 의학 전문가들 사이에서는 비만의 원인은 복잡하며 다양한 요소에 기인하고, 비만은 단순한 자제력의 문제가 아니라 식욕 조절과 에너지 대사가 관련된 복잡한 질병이라는 인식이 확산되고 있다. 그러나, 비만의 일반적인 원인으로는 섭취 에너지가 소비 에너지에 비해 지속적으로 과도하게 되는 것이므로, 비만을 예방 또는 치료하기 위한 장기적 관점에서 식이요법, 운동과 병행하여 사용될 수 있는 효과적이고 안전한 의약품이 요구되고 있다.As described above, obesity is a worldwide disease, and although it is a serious disease that causes various diseases, it is a disease that cannot be easily treated. Among medical experts, the cause of obesity is complex and is caused by various factors, and awareness is spreading that obesity is not a simple matter of self-control, but a complex disease related to appetite control and energy metabolism. However, a common cause of obesity is that intake energy is consistently excessive compared to energy consumption, so effective and safe medicines that can be used in conjunction with diet and exercise from a long-term perspective to prevent or treat obesity are required. .
현재까지 알려진 비만 치료제의 작용기전으로는 식욕 억제, 열대사 촉진, 소화 억제, 호르몬 조절 등이 있다. 이와는 구별되게 지방전구세포가 지방세포로 분화되는 과정을 저해하면 체내의 지방세포수를 조절할 수 있으며, 따라서 이러한 작용기전을 바탕으로 비만을 치료할 수 있다. 지방세포로의 분화과정은 Pref-1, Foxo1, Foxa2, SMAD-3, Wnt-10b, GATA-2, GATA-3, PPAR 등의 세포 내 조절인자 상호간의 신호전달 과정에 의하여 조절된다. 그러므로, 이러한 세포 내 신호전달물질에 영향을 줄 수 있는 약물을 스크리닝함으로써 비만 치료물질을 찾아낼 수 있다.Mechanisms of action of anti-obesity drugs known so far include suppression of appetite, promotion of heat death, inhibition of digestion, and hormone regulation. Distinguished from this, inhibition of the process of differentiation of preadipocytes into adipocytes can control the number of adipocytes in the body, and thus obesity can be treated based on this mechanism of action. The differentiation process into adipocytes is controlled by the signaling process between intracellular regulators such as Pref-1, Foxo1, Foxa2, SMAD-3, Wnt-10b, GATA-2, GATA-3, and PPAR. Therefore, it is possible to find anti-obesity substances by screening drugs that can affect these intracellular signaling substances.
일 측면에서, 본 개시물은 비만 또는 이상지질혈증의 예방 또는 치료용 약학 조성물을 제공하는 것을 목적으로 한다.In one aspect, an object of the present disclosure is to provide a pharmaceutical composition for preventing or treating obesity or dyslipidemia.
다른 측면에서, 본 개시물은 비만 또는 이상지질혈증의 개선용 식품 조성물을 제공하는 것을 목적으로 한다.In another aspect, an object of the present disclosure is to provide a food composition for improving obesity or dyslipidemia.
다른 측면에서, 본 개시물은 항산화용 조성물을 제공하는 것을 목적으로 한다.In another aspect, the present disclosure aims to provide an antioxidant composition.
다른 측면에서, 본 개시물은 항염 조성물을 제공하는 것을 목적으로 한다. In another aspect, the present disclosure aims to provide an anti-inflammatory composition.
일 측면에서, 본 개시물은 흥안독활 추출물을 유효성분으로 포함하는 비만 또는 이상지질혈증의 예방 또는 치료용 약학 조성물을 제공한다.In one aspect, the present disclosure provides a pharmaceutical composition for preventing or treating obesity or dyslipidemia comprising an extract of Heungan dokhwal as an active ingredient.
예시적인 일 구현예에서, 상기 흥안독활 추출물은 흥안독활의 지상부 추출물을 포함하는 것일 수 있다.In an exemplary embodiment, the Heungan dokhwal extract may include an aerial part extract of Heungan dokhwal.
예시적인 일 구현예에서, 상기 흥안독활 추출물은 흥안독활의 에탄올 추출물을 포함하는 것일 수 있다.In an exemplary embodiment, the Heungan dokhwal extract may include an ethanol extract of Heungan dokhwal.
예시적인 일 구현예에서, 상기 약학 조성물은 지방 축적 억제 또는 지방 분해 용도를 갖는 것일 수 있다.In an exemplary embodiment, the pharmaceutical composition may be used for inhibiting fat accumulation or decomposing fat.
예시적인 일 구현예에서, 상기 이상지질혈증은 고지혈증, 고콜레스테롤혈증 및 고중성지방혈증으로 이루어진 군에서 선택되는 1 이상인 것일 수 있다.In an exemplary embodiment, the dyslipidemia may be one or more selected from the group consisting of hyperlipidemia, hypercholesterolemia and hypertriglyceridemia.
다른 측면에서, 본 개시물은 흥안독활 추출물을 유효성분으로 포함하는 비만 또는 이상지질혈증의 개선용 식품 조성물을 제공한다.In another aspect, the present disclosure provides a food composition for the improvement of obesity or dyslipidemia comprising a heungan dokhwal extract as an active ingredient.
예시적인 일 구현예에서, 상기 흥안독활 추출물은 흥안독활의 지상부 추출물을 포함하는 것일 수 있다.In an exemplary embodiment, the Heungan dokhwal extract may include an aerial part extract of Heungan dokhwal.
예시적인 일 구현예에서, 상기 흥안독활 추출물은 흥안독활의 에탄올 추출물을 포함하는 것일 수 있다.In an exemplary embodiment, the Heungan dokhwal extract may include an ethanol extract of Heungan dokhwal.
예시적인 일 구현예에서, 상기 식품 조성물은 지방 축적 억제 또는 지방 분해 용도를 갖는 것일 수 있다.In an exemplary embodiment, the food composition may be used to inhibit fat accumulation or decompose fat.
예시적인 일 구현예에서, 상기 이상지질혈증은 고지혈증, 고콜레스테롤혈증 및 고중성지방혈증으로 이루어진 군에서 선택되는 1 이상인 것일 수 있다.In an exemplary embodiment, the dyslipidemia may be one or more selected from the group consisting of hyperlipidemia, hypercholesterolemia and hypertriglyceridemia.
다른 측면에서, 본 개시물은 흥안독활 추출물을 유효성분으로 포함하는 항산화용 조성물을 제공한다.In another aspect, the present disclosure provides an antioxidant composition comprising a heungan dokhwal extract as an active ingredient.
예시적인 일 구현예에서, 상기 흥안독활 추출물은 흥안독활의 지상부 추출물을 포함하는 것일 수 있다.In an exemplary embodiment, the Heungan dokhwal extract may include an aerial part extract of Heungan dokhwal.
예시적인 일 구현예에서, 상기 흥안독활 추출물은 흥안독활의 에탄올 추출물을 포함하는 것일 수 있다.In an exemplary embodiment, the Heungan dokhwal extract may include an ethanol extract of Heungan dokhwal.
예시적인 일 구현예에서, 상기 항산화용 조성물은 지질 산화를 억제하는 것일 수 있다.In an exemplary embodiment, the antioxidant composition may inhibit lipid oxidation.
예시적인 일 구현예에서, 상기 항산화용 조성물은 NQO1, HO-1, SOD1 및 SOD2로 이루어진 군에서 선택되는 1 이상의 항산화 관련 단백질의 발현을 증가시키는 것일 수 있다.In an exemplary embodiment, the antioxidant composition may increase the expression of one or more antioxidant-related proteins selected from the group consisting of NQO1, HO-1, SOD1 and SOD2.
다른 측면에서, 본 개시물은 흥안독활 추출물을 유효성분으로 포함하는 항염 조성물을 제공한다.In another aspect, the present disclosure provides an anti-inflammatory composition comprising Heungan dokhwal extract as an active ingredient.
예시적인 일 구현예에서, 상기 흥안독활 추출물은 흥안독활의 지상부 추출물을 포함하는 것일 수 있다.In an exemplary embodiment, the Heungan dokhwal extract may include an aerial part extract of Heungan dokhwal.
예시적인 일 구현예에서, 상기 흥안독활 추출물은 흥안독활의 에탄올 추출물을 포함하는 것일 수 있다.In an exemplary embodiment, the Heungan dokhwal extract may include an ethanol extract of Heungan dokhwal.
예시적인 일 구현예에서, 상기 항염 조성물은 염증을 억제하는 것일 수 있다.In an exemplary embodiment, the anti-inflammatory composition may inhibit inflammation.
예시적인 일 구현예에서, 상기 항염 조성물은 MCP1, ICAM-1, IL-1β, IFNγ, CD11c 및 F4/80로 이루어진 군에서 선택되는 1 이상의 염증 관련 인자의 발현을 감소시키는 것일 수 있다.In an exemplary embodiment, the anti-inflammatory composition may reduce the expression of one or more inflammation-related factors selected from the group consisting of MCP1, ICAM-1, IL-1β, IFNγ, CD11c and F4/80.
일 측면에서, 본 개시물에 개시된 기술은 비만 또는 이상지질혈증의 예방 또는 치료용 약학 조성물을 제공하는 효과가 있다.In one aspect, the technology disclosed in the present disclosure has the effect of providing a pharmaceutical composition for preventing or treating obesity or dyslipidemia.
다른 측면에서, 본 개시물에 개시된 기술은 비만 또는 이상지질혈증의 개선용 식품 조성물을 제공하는 효과가 있다.In another aspect, the technology disclosed in the present disclosure has the effect of providing a food composition for improving obesity or dyslipidemia.
다른 측면에서, 본 개시물에 개시된 기술은 항산화용 조성물을 제공하는 효과가 있다.In another aspect, the technology disclosed in this disclosure has the effect of providing a composition for antioxidant.
다른 측면에서, 본 개시물에 개시된 기술은 항염 조성물을 제공하는 효과가 있다.In another aspect, the techniques disclosed in this disclosure are effective in providing an anti-inflammatory composition.
도 1은 일 실험예에 따라 마우스의 부고환지방 조직 내 지방세포 크기를 확인한 것이다.
도 2는 일 실험예에 따라 마우스의 혈청으로부터 중성지질, 총 콜레스테롤, 고밀도콜레스테롤, 저밀도콜레스테롤 함량을 확인한 것이다.
도 3은 일 실험예에 따라 항산화 효과를 확인한 것이다.
도 4는 일 실험예에 따라 항염 효과를 확인한 것이다.
도 5는 일 실험예에 따라 AMPK의 인산화 촉진을 통한 열량 소모를 확인한 것이다.
상기 각 도면에서 알파벳 소문자의 표기는, 그룹간에 서로 다른 기호의 표기를 가진 경우 p < 0.05 유의수준에서 통계적으로 유의한 차이가 있는 것을 나타낸 것이다.Figure 1 confirms the size of adipocytes in epididymal adipose tissue of mice according to an experimental example.
Figure 2 confirms the contents of neutral lipid, total cholesterol, high-density cholesterol, and low-density cholesterol from the serum of mice according to an experimental example.
Figure 3 confirms the antioxidant effect according to an experimental example.
Figure 4 confirms the anti-inflammatory effect according to an experimental example.
Figure 5 confirms the calorie consumption through the promotion of phosphorylation of AMPK according to an experimental example.
In each of the figures, the lowercase letters of the alphabet indicate that there is a statistically significant difference at the significance level of p < 0.05 when the groups have different symbols.
이하, 본 개시물을 상세히 설명한다.Hereinafter, the present disclosure will be described in detail.
일 측면에서, 본 개시물은 흥안독활 추출물을 유효성분으로 포함하는 비만 또는 이상지질혈증의 예방, 개선 또는/및 치료용 조성물을 제공한다.In one aspect, the present disclosure provides a composition for preventing, improving, or/and treating obesity or dyslipidemia, which includes Heungan dokhwal extract as an active ingredient.
다른 측면에서, 본 개시물은 흥안독활 추출물을 유효성분으로 포함하는 항산화용 조성물을 제공한다.In another aspect, the present disclosure provides an antioxidant composition comprising a heungan dokhwal extract as an active ingredient.
또 다른 측면에서, 본 개시물은 흥안독활 추출물을 유효성분으로 포함하는 항염 조성물을 제공한다.In another aspect, the present disclosure provides an anti-inflammatory composition comprising a heungan dokhwal extract as an active ingredient.
본 개시물에서 이상지질혈증은 혈중에 총 콜레스테롤, 저밀도콜레스테롤 (LDL) 또는/및 중성지방이 증가된 상태이거나 고밀도콜레스테롤 (HDL)이 감소된 상태를 의미하는 것으로, 예시적인 일 구현예에서, 상기 이상지질혈증은 고지혈증, 고콜레스테롤혈증 및 고중성지방혈증으로 이루어진 군에서 선택되는 1 이상인 것일 수 있다.In the present disclosure, dyslipidemia refers to a state in which total cholesterol, low-density cholesterol (LDL) and/or triglyceride in the blood is increased or high-density cholesterol (HDL) is decreased. In an exemplary embodiment, the Dyslipidemia may be at least one selected from the group consisting of hyperlipidemia, hypercholesterolemia and hypertriglyceridemia.
본 개시물에서 항산화는 산화 과정을 예방, 억제, 저해, 개선 또는/및 지연시키는 효능을 의미한다.Antioxidation in this disclosure means the ability to prevent, inhibit, inhibit, ameliorate or/and retard oxidative processes.
본 개시물에서 항염은 염증 또는/및 염증 관련 질환을 예방, 억제, 저해, 개선 또는/및 치료하는 효능을 의미하는 것으로서, 염증은 체액이 조직 세포 사이에 증가하여 나타나는 부종, 혈관 확장에 따른 충혈, 발열 물질과 혈관 확장에 의한 발열, 아라키돈산 대사산물에 의한 통증 등과 같은 증상 또는 징후로 나타나고, 시간에 따라 급성, 아급성, 만성 염증질환으로 분류할 수 있고, 병태 생리에 따라 감염성, 알레르기성, 자가면역성, 독성, 대사성, 외상성 염증질환으로 분류할 수 있다.In the present disclosure, anti-inflammatory means the efficacy of preventing, inhibiting, inhibiting, improving, or/and treating inflammation or/and inflammation-related diseases, and inflammation is edema caused by an increase in body fluid between tissue cells and congestion due to vasodilation. , symptoms or signs such as fever due to pyrogens and vasodilation, pain due to metabolites of arachidonic acid, etc., and can be classified into acute, subacute, and chronic inflammatory diseases depending on time, and infectious and allergic depending on pathophysiology. , autoimmune, toxic, metabolic, and traumatic inflammatory diseases.
예시적인 일 구현예에서, 상기 염증은 비염, 부비동염, 중이염, 비인두염, 후두염, 기관지염, 천식, 만성폐쇄성폐질환, 기관지확장증, 세기관지염, 폐렴, 폐섬유화증 등의 호흡기계 염증질환; 구강염, 식도염, 위염, 소화성궤양, 과민성장증후군, 염증성장질환, 담낭염, 담도염, 췌장염, 간염 등의 소화기계 염증질환; 여드름, 접촉성 피부염, 지루성 피부염, 아토피 피부염, 건선 등의 피부 염증질환; 심내막염, 심근염, 심낭염, 혈관염, 동맥경화증, 패혈증 등의 심혈관계 염증질환; 갑상선염, 부갑상산염, 당뇨병 등의 내분비계 염증질환; 사구체신염, 신병증, 간질성 신질환, 고환염, 난소염, 자궁내막염, 질염 등의 비뇨생식계 염증질환; 류마티스관절염, 척추관절병증, 골관절염, 통풍, 전신성홍반성루프스, 전신성경화증, 근병증, 쇼그렌증후군, 베체트병, 항인지질증후군 등의 근골격계 염증질환; 혈관성치매, 알츠하이머병, 퇴행성뇌질환, 우울증, 정신분열증 등의 신경정신계 염증질환 등으로 이루어진 군으로부터 선택될 수 있다.In an exemplary embodiment, the inflammation is rhinitis, sinusitis, otitis media, nasopharyngitis, laryngitis, bronchitis, asthma, chronic obstructive pulmonary disease, bronchiectasis, bronchiolitis, pneumonia, respiratory inflammatory diseases such as pulmonary fibrosis; digestive inflammatory diseases such as stomatitis, esophagitis, gastritis, peptic ulcer, irritable bowel syndrome, inflammatory bowel disease, cholecystitis, cholangitis, pancreatitis, and hepatitis; inflammatory skin diseases such as acne, contact dermatitis, seborrheic dermatitis, atopic dermatitis, and psoriasis; cardiovascular inflammatory diseases such as endocarditis, myocarditis, pericarditis, vasculitis, arteriosclerosis, and sepsis; inflammatory diseases of the endocrine system, such as thyroiditis, parathyroidism, and diabetes; urogenital inflammatory diseases such as glomerulonephritis, nephropathy, interstitial renal disease, orchitis, oophoritis, endometritis, and vaginitis; musculoskeletal inflammatory diseases such as rheumatoid arthritis, spondyloarthropathy, osteoarthritis, gout, systemic lupus erythematosus, systemic sclerosis, myopathy, Sjogren's syndrome, Behcet's disease, and antiphospholipid syndrome; It may be selected from the group consisting of neuropsychiatric inflammatory diseases such as vascular dementia, Alzheimer's disease, degenerative brain disease, depression, and schizophrenia.
본 개시물에서 유효성분은 단독으로 목적으로 하는 활성을 나타내거나 또는 그 자체는 활성이 없는 담체 등과 함께 목적으로 하는 활성을 나타낼 수 있는 성분을 의미한다.In the present disclosure, the active ingredient refers to a component that can exhibit the desired activity alone or together with a carrier having no activity by itself.
본 개시물에서 흥안독활은 Heracleum dissectum Ledeb.이의 학명을 갖고, 재배한 것, 채취한 것 또는 시판되는 것 등 제한 없이 사용할 수 있다. 또한, 본 개시물에서 흥안독활은 그 생체뿐만 아니라 흥안독활의 가공물, 예를 들어 건조물, 분쇄물, 발효물 등 추가적인 가공에 의해 얻어진 가공물의 모든 형태를 포함하는 것을 의미한다. In the present disclosure, Heungan Dokhwal has the scientific name of Heracleum dissectum Ledeb. It can be used without limitation, such as cultivated, collected, or commercially available. In addition, in the present disclosure, Heungan Dokhwal means to include all forms of processed products obtained by additional processing, such as the living body as well as processed products of Heungan Dokhwal, for example, dried products, pulverized products, and fermented products.
예시적인 일 구현예에서, 상기 흥안독활 추출물은 흥안독활의 지상부 추출물을 포함하는 것이 바람직할 수 있다.In an exemplary embodiment, it may be preferable that the Heungan dokhwal extract includes an aerial part extract of Heungan dokhwal.
본 개시물에서 흥안독활 추출물은 흥안독활의 조추출물뿐만 아니라 추출물의 가공물, 예를 들어 건조, 농축, 분획, 발효 등 추가적인 가공에 의해 얻어진 가공물의 모든 형태를 포함하는 것을 의미한다. 또한, 본 개시물에서 흥안독활 추출물은 시판되는 것을 구입하거나, 또는 당해 기술분야에서 사용되는 통상의 추출방법을 적절하게 선택, 조합, 부가 또는 변경하여 얻어질 수 있다.In the present disclosure, Heungan Dokhwal extract means to include all forms of processed products obtained by additional processing such as drying, concentration, fractionation, fermentation, etc., as well as crude extracts of Heungan Dokhwal as well as processed products of the extract. In addition, in the present disclosure, the Heungan Dokhwal extract may be obtained by purchasing a commercially available one, or by appropriately selecting, combining, adding, or changing a conventional extraction method used in the art.
예시적인 일 구현예에서, 상기 흥안독활 추출물은 물, 탄소수 1 내지 4의 알코올 (예컨대, 메탄올, 에탄올, 프로판올, 부탄올 등), 에틸렌, 아세톤, 헥산, 에테르, 클로로포름, 에틸아세테이트, 부틸아세테이트, 디클로로메탄, N, N-디메틸포름아미드 (DMF), 염화메틸렌, 디메틸설폭사이드 (DMSO), 글리세린, 부틸렌글리콜, 프로필렌글리콜, 디프로필렌글리콜, 메틸렌클로라이드 및 디에틸에테르로 이루어진 군에서 선택되는 1 이상의 용매로 추출한 것일 수 있다.In an exemplary embodiment, the Heungan Dokhwal extract is water, alcohol having 1 to 4 carbon atoms (eg, methanol, ethanol, propanol, butanol, etc.), ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate, dichloro At least one selected from the group consisting of methane, N, N-dimethylformamide (DMF), methylene chloride, dimethyl sulfoxide (DMSO), glycerin, butylene glycol, propylene glycol, dipropylene glycol, methylene chloride and diethyl ether It may be extracted with a solvent.
예시적인 일 구현예에서, 상기 흥안독활 추출물은 흥안독활의 에탄올 추출물을 포함하는 것이 바람직할 수 있다.In an exemplary embodiment, it may be preferable that the Heungan dokhwal extract includes an ethanol extract of Heungan dokhwal.
예시적인 일 구현예에서, 상기 에탄올은 60 내지 97 부피%의 농도를 갖는 것일 수 있다. 다른 예시적인 일 구현예에서, 상기 에탄올은 60 부피% 이상, 65 부피% 이상, 70 부피% 이상, 75 부피% 이상, 80 부피% 이상 또는 85 부피% 이상이고, 97 부피% 이하, 95 부피% 이하, 90 부피% 이하, 85 부피% 이하 또는 80 부피% 이하인 농도를 갖는 것일 수 있다.In an exemplary embodiment, the ethanol may have a concentration of 60 to 97% by volume. In another exemplary embodiment, the ethanol is 60 vol% or more, 65 vol% or more, 70 vol% or more, 75 vol% or more, 80 vol% or more or 85 vol% or more, 97 vol% or less, 95 vol% Or less, it may have a concentration of 90 vol% or less, 85 vol% or less, or 80 vol% or less.
예시적인 일 구현예에서, 상기 에탄올은 물과 에탄올의 혼합 용매인 것일 수 있다.In an exemplary embodiment, the ethanol may be a mixed solvent of water and ethanol.
예시적인 일 구현예에서, 상기 흥안독활 추출물을 제조하는 방법은 초임계추출, 아임계추출, 냉침추출, 고온추출, 환류냉각추출, 고압추출, 초음파추출 등을 이용하는 방법 또는 XAD 및 HP-20을 포함한 흡착 수지를 이용하는 방법 등 당업계의 통상적인 추출방법을 사용할 수 있다. 구체적으로, 가온하며 환류 추출 또는 상온에서 환류 추출할 수 있으나, 이에 제한되지 않는다. 또한, 추출 용매는 흥안독활 건조물의 약 1 내지 15배 정도에 해당하는 용매를 가하여 추출할 수 있으며, 구체적으로 약 10배의 용매를 가하여 추출할 수 있으나, 이에 제한되는 것은 아니다. 아울러, 추출 횟수는 1 내지 5회일 수 있으며, 구체적으로 2회 반복 추출할 수 있으나, 이에 제한되는 것은 아니며, 추출 시간은 2시간 내지 10일 동안 추출할 수 있으며, 구체적으로 3일 내지 7일 동안 추출할 수 있으나, 이에 제한되는 것은 아니다.In an exemplary embodiment, the method for preparing the Heungan Dokhwal extract is a method using supercritical extraction, subcritical extraction, cold extraction, high temperature extraction, reflux cooling extraction, high pressure extraction, ultrasonic extraction, or XAD and HP-20 A conventional extraction method in the art, such as a method using an adsorption resin including Specifically, reflux extraction with heating or reflux extraction at room temperature may be performed, but is not limited thereto. In addition, the extraction solvent can be extracted by adding a solvent corresponding to about 1 to 15 times the amount of dried heungan dokhwal, and specifically, it can be extracted by adding about 10 times the solvent, but is not limited thereto. In addition, the number of extractions may be 1 to 5 times, specifically, but may be repeatedly extracted twice, but is not limited thereto, and the extraction time may be extracted for 2 hours to 10 days, specifically for 3 to 7 days. It can be extracted, but is not limited thereto.
예시적인 일 구현예에서, 상기 흥안독활 추출물을 제조하는 방법은 흥안독활 건조물을 에탄올 용매로 상온에서 추출하여 추출액을 얻은 다음, 추출액을 여과하고 감압 농축하여 흥안독활의 에탄올 추출물을 제조하는 것일 수 있다.In an exemplary embodiment, the method for preparing the Heungan Dokhwal extract may be to extract the Heungan Dokhwal dried product at room temperature with an ethanol solvent to obtain an extract, and then filter the extract and concentrate under reduced pressure to prepare an ethanol extract of Heungan Dokhwal. .
예시적인 일 구현예에서, 상기 조성물은 조성물 전체 중량을 기준으로 0.001 내지 80 중량%. 0.01 내지 50 중량% 또는 0.1 내지 10 중량%의 흥안독활 추출물을 포함하는 것일 수 있다.In an exemplary embodiment, the composition is 0.001 to 80% by weight based on the total weight of the composition. It may include 0.01 to 50% by weight or 0.1 to 10% by weight of Heungan Dokhwal extract.
본 개시물에 따른 조성물은 체중 감소, 혈중 지질 개선, 지질 산화 억제 또는/및 염증 억제 효과를 제공한다.The composition according to the present disclosure provides effects of reducing body weight, improving blood lipids, inhibiting lipid oxidation, or/and inhibiting inflammation.
예시적인 일 구현예에서, 상기 조성물은 지방 축적 억제 또는/및 지방 분해 용도를 갖는 것일 수 있다.In an exemplary embodiment, the composition may have a purpose of inhibiting fat accumulation or/or decomposing fat.
예시적인 일 구현예에서, 상기 조성물은 혈중 중성지질 감소, 혈중 총 콜레스테롤 감소, 혈중 고밀도콜레스테롤 증가 또는/및 혈중 저밀도콜레스테롤 감소 용도를 갖는 것일 수 있다.In an exemplary embodiment, the composition may be used for reducing blood triglycerides, reducing total cholesterol in the blood, increasing high-density cholesterol in the blood, and/or reducing low-density cholesterol in the blood.
예시적인 일 구현예에서, 상기 조성물은 지질 산화를 억제하는 것일 수 있다.In an exemplary embodiment, the composition may inhibit lipid oxidation.
예시적인 일 구현예에서, 상기 조성물은 NQO1, HO-1, SOD1 및 SOD2로 이루어진 군에서 선택되는 1 이상의 항산화 관련 단백질의 발현을 증가시키는 것일 수 있다.In an exemplary embodiment, the composition may increase the expression of one or more antioxidant-related proteins selected from the group consisting of NQO1, HO-1, SOD1 and SOD2.
예시적인 일 구현예에서, 상기 조성물은 지질 축적에 의한 산화적 스트레스를 완화하는 것일 수 있다.In an exemplary embodiment, the composition may relieve oxidative stress caused by lipid accumulation.
예시적인 일 구현예에서, 상기 조성물은 염증을 억제하는 것일 수 있다.In an exemplary embodiment, the composition may inhibit inflammation.
예시적인 일 구현예에서, 상기 조성물은 MCP1, ICAM-1, IL-1β, IFNγ, CD11c 및 F4/80로 이루어진 군에서 선택되는 1 이상의 염증 관련 인자의 발현을 감소시키는 것일 수 있다.In an exemplary embodiment, the composition may reduce the expression of one or more inflammation-related factors selected from the group consisting of MCP1, ICAM-1, IL-1β, IFNγ, CD11c and F4/80.
예시적인 일 구현예에서, 상기 조성물은 지질 축적에 의한 염증을 완화하는 것일 수 있다.In an exemplary embodiment, the composition may relieve inflammation caused by lipid accumulation.
예시적인 일 구현예에서, 상기 조성물은 약학 조성물인 것일 수 있다.In an exemplary embodiment, the composition may be a pharmaceutical composition.
예시적인 일 구현예에서, 상기 약학 조성물은 방부제, 안정화제, 수화제 또는 유화 촉진제, 삼투압 조절을 위한 염 및/또는 완충제 등의 약제학적 보조제 및 기타 치료적으로 유용한 물질을 추가로 함유할 수 있으며, 통상적인 방법에 따라 다양한 경구 투여제 또는 비경구 투여제 형태로 제형화할 수 있다.In an exemplary embodiment, the pharmaceutical composition may further contain pharmaceutical adjuvants and other therapeutically useful substances such as preservatives, stabilizers, hydrating agents or emulsifying accelerators, salts and/or buffers for osmotic pressure control, It can be formulated into various oral or parenteral dosage forms according to conventional methods.
상기 경구 투여제는 예를 들면, 정제, 환제, 경질 및 연질 캅셀제, 액제, 현탁제, 유화제, 시럽제, 분제, 산제, 세립제, 과립제, 펠렛제 등이 있으며, 이들 제형은 계면 활성제, 희석제 (예: 락토즈, 덱스트로즈, 수크로즈, 만니톨, 솔비톨, 셀룰로오스 및 글리신), 활택제 (예: 실리카, 탈크, 스테아르산 및 그의 마그네슘 또는 칼슘염 및 폴리에틸렌 글리콜)를 함유할 수 있다. 정제는 또한 마그네슘 알루미늄 실리케이트, 전분페이스트, 젤라틴, 트라가칸스, 메틸셀룰로오스, 나트륨 카복시메틸셀룰로오스 및 폴리비닐피롤리딘과 같은 결합제를 함유할 수 있으며, 경우에 따라 전분, 한천, 알긴산 또는 그의 나트륨 염과 같은 붕해제, 흡수제, 착색제, 향미제 및 감미제 등의 약제학적 첨가제를 함유할 수 있다. 상기 정제는 통상적인 혼합, 과립화 또는 코팅 방법에 의해 제조될 수 있다.The oral administration agent includes, for example, tablets, pills, hard and soft capsules, solutions, suspensions, emulsifiers, syrups, powders, powders, granules, granules, pellets, etc. These formulations include surfactants, diluents ( eg lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and glycine), lubricants (eg silica, talc, stearic acid and its magnesium or calcium salts and polyethylene glycol). Tablets may also contain binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and polyvinylpyrrolidine, optionally starch, agar, alginic acid or its sodium salt. It may contain pharmaceutical additives such as disintegrants, absorbents, colorants, flavors and sweeteners. The tablets may be prepared by conventional mixing, granulating or coating methods.
또한, 상기 비경구 투여 형태로는 경피 투여형 제형일 수 있으며, 예를 들어 주사제, 점적제, 연고, 로션, 겔, 크림, 스프레이, 현탁제, 유제, 패취 등의 제형일 수 있으나, 이에 제한되는 것은 아니다.In addition, the parenteral dosage form may be a transdermal dosage form, for example, it may be a dosage form such as an injection, drops, ointment, lotion, gel, cream, spray, suspension, emulsion, patch, etc., but is limited thereto. it is not going to be
예시적인 일 구현예에서, 상기 약학 조성물은 목적하는 방법에 따라 경구, 비경구, 직장, 국소, 경피, 정맥 내, 근육 내, 복강 내, 피하 등으로 투여할 수 있으며, 약학 조성물의 유효성분은 투여받을 대상의 연령, 성별, 체중, 병리 상태 및 그 심각도, 투여 경로 또는 처방자의 판단에 따라 달라질 것이다. 이러한 인자에 기초한 적용량 결정은 당업자의 수준 내에 있으며, 이의 1일 투여 용량은 예를 들어 0.001 mg/kg/일 내지 100 mg/kg/일, 보다 구체적으로는 0.5 mg/kg/일 내지 50 mg/kg/일이 될 수 있으나, 이에 제한되는 것은 아니다.In an exemplary embodiment, the pharmaceutical composition may be administered orally, parenterally, rectal, topical, transdermal, intravenous, intramuscular, intraperitoneal, subcutaneous, etc. according to the desired method, and the active ingredient of the pharmaceutical composition is It will vary depending on the age, sex, weight, pathological condition and severity of the subject to be administered, the route of administration, or the judgment of the prescriber. Determination of the application amount based on these factors is within the level of a person skilled in the art, and its daily administration dose is, for example, 0.001 mg/kg/day to 100 mg/kg/day, more specifically 0.5 mg/kg/day to 50 mg/kg/day. kg/day, but is not limited thereto.
예시적인 일 구현예에서, 상기 조성물은 식품 조성물인 것일 수 있다.In one exemplary embodiment, the composition may be a food composition.
예시적인 일 구현예에서, 상기 식품 조성물은 건강기능식품 조성물인 것일 수 있다.In an exemplary embodiment, the food composition may be a health functional food composition.
예시적인 일 구현예에서, 상기 식품 조성물은 액상 또는 고체 상태의 제형일 수 있고, 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 건강보조 식품류 등이 있고, 분말, 과립, 정제, 캡슐 또는 음료인 형태로 사용될 수 있다. 각 제형의 식품 조성물은 해당 분야에서 통상적으로 사용되는 성분들을 제형 또는 사용 목적에 따라 당업자가 어려움 없이 적의 선정하여 배합할 수 있다.In an exemplary embodiment, the food composition may be a liquid or solid formulation, for example, various foods, beverages, gum, tea, vitamin complexes, health supplements, etc., powders, granules, tablets, It can be used in capsule or beverage form. The food composition of each formulation can be formulated by selecting components commonly used in the field without difficulty by those skilled in the art according to the formulation or purpose of use.
예시적인 일 구현예에서, 본 개시물에 따른 조성물에 함유될 수 있는 액체 성분에는 특별한 제한이 없으며, 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가성분으로 포함할 수 있다. 상기 천연 탄수화물의 예로는 모노사카라이드, 포도당, 과당 등의 디사카라이드, 말토스, 슈크로스 등의 폴리사카라이드, 덱스트린, 시클로덱스트린 등의 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당 알코올 등이 있다. 상기 향미제로는 천연 향미제 (타우마틴, 스테비아 추출물) 및 합성 향미제 (예를 들어 사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 개시물에 개시된 조성물 100 중량부 당 일반적으로 약 0.01 내지 0.04 중량부, 바람직하게는 0.02 내지 0.03 중량부이다.In one exemplary embodiment, there is no particular limitation on the liquid component that may be contained in the composition according to the present disclosure, and various flavoring agents or natural carbohydrates may be included as additional components like conventional beverages. Examples of the natural carbohydrate include monosaccharides, disaccharides such as glucose and fructose, polysaccharides such as maltose and sucrose, common sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. etc. As the flavoring agent, natural flavoring agents (thaumatin, stevia extract) and synthetic flavoring agents (eg, saccharin, aspartame, etc.) can be advantageously used. The proportion of the natural carbohydrate is generally about 0.01 to 0.04 parts by weight, preferably 0.02 to 0.03 parts by weight per 100 parts by weight of the composition disclosed in this disclosure.
예시적인 일 구현예에서, 상기 식품 조성물은 일 측면에서 여러 가지 영양제, 비타민, 광물 (전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제 (치즈, 초콜릿 등), 펙트산 및 그 염, 알긴산 및 그 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 포함할 수 있다. 다른 측면에서 천연 과일 주스 및 야채 음료의 제조를 위한 과육을 포함할 수 있다. 상기 성분들은 독립적으로 또는 조합하여 사용될 수 있다. 상기 첨가제의 비율은 다양할 수 있으나, 본 개시물에 개시된 조성물 100 중량부 당 약 0.001 내지 20 중량부의 범위에서 선택되는 것이 일반적이다.In an exemplary embodiment, the food composition in one aspect includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and enhancers (cheese, chocolate, etc.), pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, and the like. In another aspect, it may include fruit pulp for the preparation of natural fruit juices and vegetable beverages. These components may be used independently or in combination. The proportions of these additives can vary, but are generally selected from the range of about 0.001 to 20 parts by weight per 100 parts by weight of the composition disclosed in this disclosure.
예시적인 일 구현예에서, 상기 조성물은 화장료 조성물인 것일 수 있다.In an exemplary embodiment, the composition may be a cosmetic composition.
예시적인 일 구현예에서, 상기 화장료 조성물에는 흥안독활 추출물 이외에 기능성 첨가물 및 일반적인 화장료 조성물에 포함되는 성분이 추가로 포함될 수 있다. 상기 기능성 첨가물로는 수용성 비타민, 유용성 비타민, 고분자 펩티드, 고분자 다당, 스핑고 지질 및 해초 엑기스로 이루어진 군에서 선택된 성분을 포함할 수 있다. 이외에 포함되는 배합 성분으로서는 유지 성분, 보습제, 에몰리엔트제, 계면 활성제, 유기 및 무기 안료, 유기 분체, 자외선 흡수제, 방부제, 살균제, 산화 방지제, 식물 추출물, pH 조정제, 알콜, 색소, 향료, 혈행 촉진제, 냉감제, 제한(制汗)제, 정제수 등을 들 수 있다.In an exemplary embodiment, the cosmetic composition may further include functional additives and components included in general cosmetic compositions in addition to the Heungan Dokhwal extract. The functional additive may include a component selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, high-molecular peptides, high-molecular polysaccharides, sphingolipids, and seaweed extracts. Ingredients other than those included include fats and oils, moisturizers, emollients, surfactants, organic and inorganic pigments, organic powders, ultraviolet absorbers, preservatives, bactericides, antioxidants, plant extracts, pH adjusters, alcohols, pigments, fragrances, blood circulation accelerators, cooling agents, antiperspirants, purified water and the like.
상기 화장료 조성물은 제형이 특별히 한정되지 않으며, 목적하는 바에 따라 적절히 선택할 수 있다. 예를 들어, 스킨로션, 스킨소프너, 스킨토너, 아스트린젠트, 로션, 밀크로션, 모이스쳐 로션, 영양로션, 맛사지크림, 영양크림, 모이스처크림, 핸드크림, 파운데이션, 에센스, 영양에센스, 팩, 비누, 클렌징폼, 클렌징로션, 클렌징크림, 바디로션 및 바디클린저로 이루어진 군으로부터 선택된 어느 하나 이상의 제형으로 제조될 수 있으나, 이에 제한되는 것은 아니다.The formulation of the cosmetic composition is not particularly limited, and may be appropriately selected according to the purpose. For example, skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nutrient lotion, massage cream, nutrient cream, moisture cream, hand cream, foundation, essence, nutrient essence, pack, soap, cleansing It may be prepared in one or more formulations selected from the group consisting of foam, cleansing lotion, cleansing cream, body lotion and body cleanser, but is not limited thereto.
본 개시물에 따른 조성물의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물섬유, 식물섬유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the composition according to the present disclosure is a paste, cream or gel, animal fiber, vegetable fiber, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide as a carrier component etc. can be used.
본 개시물에 따른 조성물의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the composition according to the present disclosure is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component, and in particular, in the case of a spray, additionally chlorofluoro propellants such as hydrocarbons, propane/butane or dimethyl ether.
본 개시물에 따른 조성물의 제형이 용액 또는 유탁액의 경우에는 담체 성분으로서 용매, 용매화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the composition according to the present disclosure is a solution or emulsion, a solvent, solvating agent or emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, fatty acid esters of propylene glycol, 1,3-butyl glycol oil, glycerol aliphatic esters, polyethylene glycol or sorbitan.
본 개시물에 따른 조성물의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the composition according to the present disclosure is a suspension, water as a carrier component, liquid diluents such as ethanol or propylene glycol, ethoxylated isostearyl alcohols, suspending agents such as polyoxyethylene sorbitol esters and polyoxyethylene sorbitan esters , microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tracanth, and the like can be used.
본 개시물에 따른 조성물의 제형이 계면-활성제 함유 클린징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 리놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the composition according to the present disclosure is a surfactant-containing cleanser, as a carrier component, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosyl nates, fatty acid amide ether sulfates, alkylamidobetaines, fatty alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, linolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.
이하, 실시예를 통하여 본 개시물을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 개시물을 예시하기 위한 것으로서, 본 개시물의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지 않는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.Hereinafter, the present disclosure will be described in more detail through examples. These examples are only for exemplifying the present disclosure, and it will be apparent to those skilled in the art that the scope of the present disclosure is not to be construed as being limited by these examples.
실시예 1. 흥안독활 추출물 제조Example 1. Heungan Dokhwal Extract Preparation
흥안독활 (Heracleum dissectum Ledeb.) 지상부 건조물 (20 g)에 200 ml의 에탄올 (약 95-96%(v/v) 농도)을 가한 후 7일 동안 상온에서 추출하고 거름종이를 사용하여 에탄올 가용부만을 회수하였다. 이 과정을 2회 반복 실시한 다음, 에탄올 가용부를 감압농축하여 흥안독활의 에탄올 추출물 (3 g)을 얻었다.Heungan Dokhwal ( Heracleum dissectum Ledeb.) After adding 200 ml of ethanol (approximately 95-96% (v/v) concentration) to the dried above-ground part (20 g), extraction was performed at room temperature for 7 days, and only the ethanol-soluble part was recovered using filter paper. After repeating this process twice, the ethanol-soluble portion was concentrated under reduced pressure to obtain an ethanol extract (3 g) of Heungan Dokhwal.
실험예Experimental example 1. 체중 및 1. Weight and 백색지방white fat 무게 감소 weight loss
C57BL/6 마우스 (male, 8주령)를 (주)중앙실험동물에서 입수하여 체중에 따라 4개의 실험군 (군당 n=8)으로 나누고, 8주간 고지방 식이 (high fat diet, 60% fat calorie)를 제공하여 비만을 유도하였다. 정상대조군은 일반 식이 (10% fat calorie)를 제공하였다.C57BL/6 mice (male, 8 weeks old) were obtained from Central Experimental Animals Co., Ltd., divided into 4 experimental groups (n=8 per group) according to body weight, and 8 weeks of high fat diet (high fat diet, 60% fat calorie) provided to induce obesity. The normal control group was provided with a normal diet (10% fat calorie).
구체적으로, 정상 대조군 (ND)은 일반 식이를 먹이면서 0.5% CMC를 매일 경구투여하였으며, 고지방 식이 대조군 (HFD)은 고지방 식이를 먹이면서 0.5% CMC를 매일 경구투여하였으며, 양성 대조군 (ORL)은 고지방 식이를 먹이면서 시판 항비만 약물인 올리스텟 (orlistat)을 30 mg/kg 농도로 0.5% CMC에 녹여 매일 경구투여하였으며, 흥안독활 실험군 (HD)은 고지방 식이를 먹이면서 상기 실시예 1에서 제조한 흥안독활 에탄올 추출물을 50 mg/kg 농도로 0.5% CMC에 녹여 매일 경구투여하였다. Specifically, the normal control group (ND) was orally administered 0.5% CMC daily while feeding a normal diet, the high-fat diet control group (HFD) was orally administered 0.5% CMC daily while feeding a high-fat diet, and the positive control group (ORL) was Orlistat, a commercially available anti-obesity drug, was dissolved in 0.5% CMC at a concentration of 30 mg/kg and administered orally daily while feeding a high-fat diet. An ethanol extract of Heungan Dokhwal was dissolved in 0.5% CMC at a concentration of 50 mg/kg and administered orally daily.
8주간의 실험 기간 종료 후, 모든 투여군의 혈청을 수집하고, 지방 조직을 적출하여 무게를 측정하였으며, 혈청 및 지방 조직 내 관련 지표를 확인하였다. 체중의 증감은 매주 1회 모든 마우스의 무게를 측정하여 기록하였다. After the 8-week experimental period, serum from all administration groups was collected, adipose tissue was removed and weighed, and relevant indicators in serum and adipose tissue were confirmed. The change in body weight was recorded by measuring the weight of all mice once a week.
그 결과, 표 1에 기재된 바와 같이 흥안독활 추출물을 먹인 실험군 (HD)의 종료 체중과 체중 증가량이 고지방 식이 대조군 (HFD)에 비해 감소하였고, 3가지의 백색지방 조직 무게도 고지방 식이 대조군 (HFD)에 비해 모두 유의적으로 감소하였다.As a result, as shown in Table 1, the end weight and weight gain of the experimental group (HD) fed with Heungan Dokhwal extract were reduced compared to the high-fat diet control group (HFD), and the three white adipose tissue weights were also compared to the high-fat diet control group (HFD) All significantly decreased compared to .
상기 표 1에서 알파벳 소문자의 표기는, 그룹간에 서로 다른 기호의 표기를 가진 경우 p < 0.05 유의수준에서 통계적으로 유의한 차이가 있는 것을 나타낸 것이다.In Table 1, the lowercase letters of the alphabet indicate that there is a statistically significant difference at the significance level of p < 0.05 when the groups have different symbols.
실험예 2. 부고환지방 조직 내 지방세포 크기 감소Experimental Example 2. Reducing the size of fat cells in epididymal fat tissue
상기 실험예 1에서 얻은 부고환지방 조직을 H&E 염색법으로 염색한 뒤, 이를 현미경으로 관찰하고 지방세포 크기를 측정하여 도 1에 나타내었다.After staining the epididymal adipose tissue obtained in Experimental Example 1 with the H&E staining method, it was observed under a microscope and the size of adipocytes was measured, which is shown in FIG.
도 1에 나타낸 바와 같이, 일반 식이에 비하여 고지방 식이를 투여한 실험군의 부고환지방 조직에서 직경이 큰 지방세포 비율 및 평균 지방세포 크기가 증가하였고, 흥안독활 추출물을 경구투여함으로써 직경이 큰 지방세포 비율 및 평균 지방세포 크기가 감소하는 것을 확인하였다. 이는 흥안독활 추출물이 지방을 분해하고 부고환지방 조직을 이루고 있는 지방세포의 크기를 감소시키는 효과가 있음을 나타낸다.As shown in Figure 1, the proportion of large-diameter adipocytes and average adipocyte size increased in the epididymal adipose tissue of the experimental group administered with the high-fat diet compared to the general diet, and the proportion of large-diameter adipocytes by orally administering Heungan Dokhwal extract And it was confirmed that the average adipocyte size decreased. This indicates that the Heungan Dokhwal extract has the effect of decomposing fat and reducing the size of adipocytes constituting the epididymal fat tissue.
실험예Experimental example 3. 혈중 지질 및 혈중 콜레스테롤 개선 3. Improves blood lipids and blood cholesterol
상기 실험예 1에서 얻은 혈청으로부터 중성지질 함량, 총 콜레스테롤 함량, 고밀도콜레스테롤 함량 (HDL), 저밀도콜레스테롤 함량 (LDL)을 시판 진단키트를 이용하여 분석하였으며, 그 결과를 도 2에 나타내었다. The triglyceride content, total cholesterol content, high-density cholesterol content (HDL), and low-density cholesterol content (LDL) of the serum obtained in Experimental Example 1 were analyzed using a commercially available diagnostic kit, and the results are shown in FIG. 2 .
도 2에 나타낸 바와 같이, 일반 식이에 비하여 고지방 식이를 투여한 실험군의 혈청 내 중성지질, 총 콜레스테롤, 고밀도콜레스테롤, 저밀도콜레스테롤 함량이 모두 증가하였고, 흥안독활 추출물을 경구투여함으로써 중성지질, 총 콜레스테롤, 저밀도콜레스테롤 함량은 감소하고 혈중 지질 개선에 도움을 주는 것으로 알려져 있는 고밀도콜레스테롤 함량은 높게 유지되는 것을 확인하였다. 이는 흥안독활 추출물이 혈중 지질과 혈중 총 콜레스테롤 함량을 낮추고, 고밀도콜레스테롤과 저밀도콜레스테롤 함량비를 개선하여 혈중 지질 상태를 개선하는 효과가 있음을 나타낸다.As shown in Figure 2, compared to the general diet, the triglyceride, total cholesterol, high-density cholesterol, and low-density cholesterol contents in the serum of the experimental group administered with the high-fat diet all increased, and by oral administration of Heungan Dokhwal extract, neutral lipid, total cholesterol, It was confirmed that the low-density cholesterol content decreased and the high-density cholesterol content, which is known to help improve blood lipids, remained high. This indicates that the Heungan Dokhwal extract has the effect of improving blood lipid status by lowering blood lipid and blood total cholesterol content and improving high-density cholesterol and low-density cholesterol content ratio.
실험예Experimental example 4. 항산화 4. Antioxidants
상기 실험예 1에서 얻은 부고환지방 조직에서 지질 산화 손상 지표인 MDA 함량을 상용 진단키트로 분석하고, 단백질을 추출하여 항산화 기작 관련 단백질의 발현을 웨스턴 블랏 (Western blot)으로 통상의 방법에 따라 측정하였다.In the epididymal adipose tissue obtained in Experimental Example 1, the MDA content, which is an index of lipid oxidation damage, was analyzed with a commercial diagnostic kit, and the protein was extracted and the expression of antioxidant mechanism-related proteins was measured by Western blot according to a conventional method. .
도 3에 나타낸 바와 같이, 일반 식이에 비하여 고지방 식이를 투여한 실험군의 부고환지방 조직에서 지질 산화 손상 지표인 MDA의 함량이 증가하였고, 흥안독활 추출물을 경구투여함으로써 MDA의 함량이 감소하는 것을 확인하였다. 또한, 흥안독활 추출물을 경구투여한 마우스의 부고환지방에서 항산화 기작과 관련된 단백질 (NQO1, HO-1, SOD1 및 SOD2)의 발현이 증가하는 것을 확인하였다. 이는 흥안독활 추출물이 지질 산화를 억제하고, 산화적 스트레스를 저해할 수 있는 효과가 있음을 나타낸다. As shown in Figure 3, the content of MDA, which is an indicator of lipid oxidation damage, increased in the epididymal adipose tissue of the experimental group administered with the high-fat diet compared to the general diet, and it was confirmed that the content of MDA decreased by oral administration of Heungan Dokhwal extract . In addition, it was confirmed that the expression of proteins (NQO1, HO-1, SOD1 and SOD2) related to antioxidant mechanisms increased in the epididymal fat of mice to which Heungan Dokhwal extract was orally administered. This indicates that the Heungan dokhwal extract has the effect of inhibiting lipid oxidation and inhibiting oxidative stress.
실험예 5. 항염Experimental Example 5. Anti-inflammatory
상기 실험예 1에서 얻은 혈청으로부터 염증 관련 사이토카인인 인터루킨-1β (IL-1β) 함량을 상용 진단키트로 분석하고, 부고환지방 조직에서 mRNA를 추출하여 염증 관련 인자의 발현을 RT-PCR 어세이로 통상의 방법에 따라 측정하였다.From the serum obtained in Experimental Example 1, the content of interleukin-1β (IL-1β), an inflammation-related cytokine, was analyzed with a commercial diagnostic kit, mRNA was extracted from epididymal fat tissue, and the expression of inflammation-related factors was measured by RT-PCR assay. It was measured according to a conventional method.
도 4에 나타낸 바와 같이, 일반 식이에 비하여 고지방 식이를 투여한 실험군의 혈청에서 IL-1β의 함량이 증가하였고, 흥안독활 추출물을 경구투여함으로써 해당 물질의 함량이 감소하는 것을 확인하였다. 또한, 흥안독활 추출물을 경구투여한 마우스의 부고환지방에서 염증 관련 인자 (케모카인; MCP1, 세포 접착 단백질; ICAM-1, 사이토카인; IL-1β 및 IFNγ, 대식세포 마커; CD11c 및 F4/80)의 발현이 감소하는 것을 확인하였다. 이는 흥안독활 추출물이 염증 관련 스트레스를 저해할 수 있는 효과가 있음을 나타낸다.As shown in Figure 4, it was confirmed that the content of IL-1β increased in the serum of the experimental group administered with the high-fat diet compared to the general diet, and the content of the substance decreased by orally administering the Heungan Dokhwal extract. In addition, the level of inflammation-related factors (chemokines; MCP1, cell adhesion protein; ICAM-1, cytokines; IL-1β and IFNγ, macrophage markers; CD11c and F4/80) in the epididymal fat of mice orally administered with Heungan Dokhwal extract It was confirmed that expression decreased. This indicates that the Heungan Dokhwal extract has the effect of inhibiting inflammation-related stress.
실험예Experimental example 6. 6. AMPKAMPK 인산화 촉진을 통한 열량 소모 Calorie consumption by promoting phosphorylation
상기 실험예 1에서 얻은 부고환지방 조직에서 단백질을 추출하여 열량 소모 관련 단백질 발현을 웨스턴 블랏으로 통상의 방법에 따라 측정하였다.Proteins were extracted from the epididymal adipose tissue obtained in Experimental Example 1, and the expression of proteins related to calorie consumption was measured by Western blotting according to a conventional method.
도 5에 나타낸 바와 같이, 흥안독활 추출물을 경구투여한 마우스에서 AMPK의 인산화가 높아졌으며, cytochrome C (cyto C)의 함량 또한 증가하였다. 이는 흥안독활 추출물이 AMPK의 인산화를 유도하여 열량 소모를 통하여 체중을 감소할 수 있는 효과가 있음을 나타낸다.As shown in Figure 5, the phosphorylation of AMPK was increased in mice orally administered with Heungan dokhwal extract, and the content of cytochrome C (cyto C) was also increased. This indicates that the Heungan dokhwal extract has the effect of reducing body weight through calorie consumption by inducing phosphorylation of AMPK.
본 개시물의 일 측면에 따른 조성물의 제형예를 아래에서 설명하나, 다른 여러 가지 제형으로도 응용 가능하며, 이는 본 개시물을 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Formulation examples of the composition according to one aspect of the present disclosure will be described below, but can also be applied to various other formulations, which are only intended to be specifically described, not intended to limit the present disclosure.
제형예formulation example 1. One. 연질캅셀제soft capsules
흥안독활 추출물 150 mg, 팜유 2 mg, 팜경화유 8 mg, 황납 4 mg 및 레시틴 6 mg을 혼합하고, 통상의 방법에 따라 1 캡슐당 400 mg씩 충진하여 연질캅셀제를 제조하였다.150 mg of Heungan Dokhwal extract, 2 mg of palm oil, 8 mg of hydrogenated palm oil, 4 mg of yellow wax, and 6 mg of lecithin were mixed, and 400 mg per capsule was filled according to a conventional method to prepare soft capsules.
제형예formulation example 2. 정제 2. Tablets
흥안독활 추출물 150 mg, 포도당 100 mg, 홍삼 추출물 50 mg, 전분 96 mg 및 마그네슘 스테아레이트 4 mg을 혼합하고 30% 에탄올을 40 mg 첨가하여 과립을 형성한 후, 60 ℃에서 건조하고 타정기를 이용하여 정제로 타정하였다.150 mg of Heungan Dokhwal extract, 100 mg of glucose, 50 mg of red ginseng extract, 96 mg of starch, and 4 mg of magnesium stearate were mixed, and 40 mg of 30% ethanol was added to form granules, dried at 60 ° C, and using a tablet press. Compressed into tablets.
제형예formulation example 3. 과립제 3. Granules
흥안독활 추출물 150 mg, 포도당 100 mg, 홍삼 추출물 50 mg 및 전분 600 mg을 혼합하고 30% 에탄올을 100 mg 첨가하여 과립을 형성한 후, 60 ℃에서 건조하여 과립을 형성한 다음 포에 충진하였다. 내용물의 최종 중량은 1 g으로 하였다.150 mg of Heungan Dokhwal extract, 100 mg of glucose, 50 mg of red ginseng extract and 600 mg of starch were mixed and 100 mg of 30% ethanol was added to form granules, and then dried at 60 ° C to form granules and then filled into bags. The final weight of the content was 1 g.
제형예formulation example 4. 드링크제 4. Drinks
흥안독활 추출물 150 mg, 포도당 10 g, 홍삼 추출물 50 mg, 구연산 2 g 및 정제수 187.8 g을 혼합하고 병에 충진하였다. 내용물의 최종 용량은 200 ml로 하였다.150 mg of Heungan Dokhwal extract, 10 g of glucose, 50 mg of red ginseng extract, 2 g of citric acid, and 187.8 g of purified water were mixed and filled into a bottle. The final volume of the content was 200 ml.
제형예 5. 건강식품의 제조Formulation Example 5. Manufacture of health food
흥안독활 추출물.......................... 1000 ㎎ Heungan Dokhwal Extract ............ 1000 mg
비타민 혼합물 vitamin mixture
비타민 A 아세테이트.......................70 ㎍ Vitamin A Acetate .................70 μg
비타민 E ................................ 1.0 ㎎ Vitamin E ................................ 1.0 mg
비타민 B1................................ 0.13 ㎎ Vitamin B1........................... 0.13 mg
비타민 B2 ............................... 0.15 ㎎ Vitamin B2 ................... 0.15 mg
비타민 B6................................ 0.5 ㎎ Vitamin B6................................ 0.5 mg
비타민 B12............................... 0.2 ㎍ Vitamin B12........................... 0.2 μg
비타민 C.................................. 10 ㎎ Vitamin C................................. 10 mg
비오틴.................................... 10 ㎍ Biotin ................................. 10 μg
니코틴산아미드............................ 1.7 ㎎ Nicotinic acid amide ........................... 1.7 mg
엽산...................................... 50 ㎍ Folic acid ................................ 50 μg
판토텐산 칼슘............................. 0.5 ㎎ Calcium Pantothenate ................... 0.5 mg
무기질 혼합물 mineral mixture
황산제1철................................. 1.75 ㎎ Ferrous Sulphate ........................... 1.75 mg
산화아연.................................. 0.82 ㎎ Zinc Oxide ................................. 0.82 mg
탄산마그네슘.............................. 25.3 ㎎ Magnesium Carbonate ................... 25.3 mg
제1인산칼륨............................... 15 ㎎ Potassium Phosphate Monobasic ................... 15 mg
제2인산칼슘............................... 55 ㎎ Dibasic Calcium Phosphate ................... 55 mg
구연산칼륨................................ 90 ㎎ Potassium citrate ................... 90 mg
탄산칼슘................................. 100 ㎎ Calcium Carbonate ................... 100 mg
염화마그네슘.............................. 24.8 ㎎ Magnesium Chloride ................... 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강식품 제조방법에 따라 상기의 성분을 혼합한 다음 과립을 제조하고, 통상의 방법에 따라 건강식품 조성물 제조에 사용할 수 있다.Although the composition ratio of the above vitamin and mineral mixture was prepared by mixing ingredients suitable for relatively healthy food in a preferred embodiment, the mixing ratio may be arbitrarily modified. Granules are prepared and can be used for preparing health food compositions according to conventional methods.
제형예formulation example 6. 건강음료의 제조 6. Manufacture of health drinks
흥안독활 추출물......................... 1000 ㎎ Heungan Dokhwal Extract ............ 1000 mg
구연산.................................. 1000 ㎎ Citric Acid ................................. 1000 mg
올리고당................................. 100 g Oligosaccharides ................................. 100 g
매실농축액................................ 2 g Plum concentrate .................. 2 g
타우린.................................... 1 g Taurine ................................. 1 g
정제수를 가하여 전체..................... 900 ㎖ Add purified water to make a total of 900 ml
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음 약 1시간 동안 85 ℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2ℓ 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관하였다. 이후, 통상의 방법에 따라 건강음료 조성물 제조에 사용하였다.After mixing the above components according to a conventional health drink manufacturing method, stirring and heating at 85 ° C. for about 1 hour, the resulting solution was filtered and obtained in a sterilized 2ℓ container, sealed and sterilized, and then stored in a refrigerator. Then, it was used to prepare a health drink composition according to a conventional method.
상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 제형예로 혼합 조성하였지만 수요계층이나, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합 비율을 임의로 변형 실시하여도 무방하다. 본 발명이 속한 기술 분야에서 통상의 지식을 가진 자라면 상기 내용을 바탕으로 본 발명의 범주 내에서 다양한 응용 및 변형을 행하는 것이 가능할 것이다.Although the composition ratio is a mixture of ingredients suitable for a relatively favorite beverage in a preferred formulation example, the mixing ratio may be arbitrarily modified according to regional and ethnic preferences such as the class of demand, the country of demand, and the purpose of use. Those skilled in the art to which the present invention pertains will be able to make various applications and modifications within the scope of the present invention based on the above information.
제형예formulation example 7. 로션 7. Lotion
하기 표 2에 기재된 조성에 따라 통상적인 방법으로 로션을 제조하였다.A lotion was prepared in a conventional manner according to the composition shown in Table 2 below.
제형예 8. 크림Formulation Example 8. Cream
하기 표 3에 기재된 조성에 따라 통상적인 방법으로 크림을 제조하였다.Cream was prepared in a conventional manner according to the composition shown in Table 3 below.
제형예 9. 팩Formulation Example 9. Pack
하기 표 4에 기재된 조성에 따라 통상적인 방법으로 팩을 제조하였다.A pack was prepared in a conventional manner according to the composition shown in Table 4 below.
이상, 본 개시물의 특정한 부분을 상세히 기술하였는바, 당업계의 통상의 지식을 가진 자에게 있어서, 이러한 구체적인 기술은 단지 바람직한 실시 태양일 뿐이며, 이에 의해 본 개시물의 범위가 제한되는 것이 아닌 점은 명백할 것이다. 따라서 본 개시물의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의해 정의된다고 할 것이다.As above, specific parts of the present disclosure have been described in detail, and for those skilled in the art, it is clear that these specific descriptions are only preferred embodiments, and the scope of the present disclosure is not limited thereby. something to do. Accordingly, the substantial scope of the disclosure will be defined by the appended claims and their equivalents.
Claims (20)
상기 추출물은 탄소수 1 내지 4의 알코올을 용매로 이용하여 추출한 것인, 비만 또는 이상지질혈증의 예방 또는 치료용 약학 조성물.
Contains the extract of the aerial part of Heungan Dokhwal as an active ingredient,
The extract is a pharmaceutical composition for preventing or treating obesity or dyslipidemia, which is extracted using an alcohol having 1 to 4 carbon atoms as a solvent.
상기 추출물은 에탄올을 용매로 이용하여 추출한 것인, 비만 또는 이상지질혈증의 예방 또는 치료용 약학 조성물.
According to claim 1,
The extract is a pharmaceutical composition for the prevention or treatment of obesity or dyslipidemia, which is extracted using ethanol as a solvent.
상기 약학 조성물은 지방 축적 억제 또는 지방 분해 용도를 갖는 것인, 비만 또는 이상지질혈증의 예방 또는 치료용 약학 조성물.
According to claim 1,
The pharmaceutical composition is a pharmaceutical composition for preventing or treating obesity or dyslipidemia, which has a purpose of inhibiting fat accumulation or decomposing fat.
상기 이상지질혈증은 고지혈증, 고콜레스테롤혈증 및 고중성지방혈증으로 이루어진 군에서 선택되는 1 이상인, 비만 또는 이상지질혈증의 예방 또는 치료용 약학 조성물.
According to claim 1,
The dyslipidemia is at least one selected from the group consisting of hyperlipidemia, hypercholesterolemia and hypertriglyceridemia, a pharmaceutical composition for preventing or treating obesity or dyslipidemia.
상기 추출물은 탄소수 1 내지 4의 알코올을 용매로 이용하여 추출한 것인, 비만 또는 이상지질혈증의 개선용 식품 조성물.
Contains the extract of the aerial part of Heungan Dokhwal as an active ingredient,
The extract is a food composition for improving obesity or dyslipidemia, which is extracted using an alcohol having 1 to 4 carbon atoms as a solvent.
상기 추출물은 에탄올을 용매로 이용하여 추출한 것인, 비만 또는 이상지질혈증의 개선용 식품 조성물.
According to claim 6,
The extract is a food composition for improving obesity or dyslipidemia, which is extracted using ethanol as a solvent.
상기 식품 조성물은 지방 축적 억제 또는 지방 분해 용도를 갖는 것인, 비만 또는 이상지질혈증의 개선용 식품 조성물.
According to claim 6,
The food composition is a food composition for improving obesity or dyslipidemia, which has a purpose of inhibiting fat accumulation or decomposing fat.
상기 이상지질혈증은 고지혈증, 고콜레스테롤혈증 및 고중성지방혈증으로 이루어진 군에서 선택되는 1 이상인, 비만 또는 이상지질혈증의 개선용 식품 조성물.
According to claim 6,
The dyslipidemia is at least one selected from the group consisting of hyperlipidemia, hypercholesterolemia and hypertriglyceridemia, food composition for improvement of obesity or dyslipidemia.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200078514A KR102466616B1 (en) | 2020-06-26 | 2020-06-26 | A composition for anti-obesity, anti-dyslipidemia, anti-oxidation or anti-inflammation comprising extracts of heracleum dissectum |
PCT/KR2021/007648 WO2021261844A1 (en) | 2020-06-26 | 2021-06-18 | Anti-obesity, anti-dyslipidemia, antioxidant or anti-inflammatory composition containing angelica dahurica extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200078514A KR102466616B1 (en) | 2020-06-26 | 2020-06-26 | A composition for anti-obesity, anti-dyslipidemia, anti-oxidation or anti-inflammation comprising extracts of heracleum dissectum |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20220000640A KR20220000640A (en) | 2022-01-04 |
KR102466616B1 true KR102466616B1 (en) | 2022-11-15 |
Family
ID=79281569
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020200078514A KR102466616B1 (en) | 2020-06-26 | 2020-06-26 | A composition for anti-obesity, anti-dyslipidemia, anti-oxidation or anti-inflammation comprising extracts of heracleum dissectum |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR102466616B1 (en) |
WO (1) | WO2021261844A1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106674311A (en) * | 2016-12-27 | 2017-05-17 | 西安交通大学 | Benzofuran glycoside compounds as well as preparation method and application thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101445966B1 (en) | 2013-03-18 | 2014-10-01 | 동의대학교 산학협력단 | A composition comprising Amomum cardamomum L. extracts having anti-obesity activity |
KR102099147B1 (en) * | 2018-07-27 | 2020-04-09 | 한남대학교 산학협력단 | Composition for preventing, ameliorating or treating obesity comprising Heracleum moellendorffii root and Torilis japonica mixed extract as effective component |
-
2020
- 2020-06-26 KR KR1020200078514A patent/KR102466616B1/en active IP Right Grant
-
2021
- 2021-06-18 WO PCT/KR2021/007648 patent/WO2021261844A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106674311A (en) * | 2016-12-27 | 2017-05-17 | 西安交通大学 | Benzofuran glycoside compounds as well as preparation method and application thereof |
Non-Patent Citations (1)
Title |
---|
FOOD CHEMISTRY, VOL. 214, pp. 572~579 (2016.07.11.)* |
Also Published As
Publication number | Publication date |
---|---|
WO2021261844A1 (en) | 2021-12-30 |
KR20220000640A (en) | 2022-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2081566B1 (en) | Improved biological effects of compositions comprising rosmarinic acid | |
KR101150643B1 (en) | A composition comprising the compounds isolated from the Inulae Flos extract of Inula japonica Thunberg having anti-inflammatory or anti-allergic activity | |
KR102478724B1 (en) | A composition for diabetes or cardiovascular disease treatment comprising a citrus fermented kombucha | |
KR20180077927A (en) | Composition for whitening, antioxidizing or antibacterial comprising Paeonia lactiflora extract or fractions thereof | |
KR20170053407A (en) | Composition containing alpha linoleic acid isolated from perilla seed oil | |
WO2011043212A1 (en) | Ceramide production enhancer and moisturizing agent | |
JP5702961B2 (en) | Glutathione production promoter and pharmaceutical having glutathione production promotion action | |
KR102466616B1 (en) | A composition for anti-obesity, anti-dyslipidemia, anti-oxidation or anti-inflammation comprising extracts of heracleum dissectum | |
KR101731075B1 (en) | Method for preparing of chaga mushroom extraction containing high concentrated betulin or betulic acid | |
JP2022552232A (en) | Mono-hydroxy or di-hydroxy derivatives of polyunsaturated fatty acids, methods for their production and uses thereof | |
KR20170091804A (en) | Composition for treating, improving or preventing allergic disease | |
KR101807080B1 (en) | Antioxidant or antiinflammatory composition comprising clamworm | |
JP2008050297A (en) | SKIN FUNCTION-IMPROVING AGENT CONTAINING gamma-AMINOBUTYRIC ACID AND SPHINGOLIPID | |
KR20130124724A (en) | Composition for retarding skin aging containing extract of ixeris dentata | |
KR102085575B1 (en) | Composition for preventing, ameliorating or treating inflammation comprising Siraitia grosvenori residual extract as effective component | |
KR101436213B1 (en) | Compositions for prevention and/or treatment of obesity comprising extracts of Boehmeria sieboldiana | |
KR102023053B1 (en) | An anti-inflammatory or immunological enhancing composition comprising a Halocynthia aurantium tunic fatty acid as an active ingredient | |
EP3750546A1 (en) | Glycerol release promoter | |
JP5689247B2 (en) | Ceramide production promoter and moisturizer | |
KR20190053369A (en) | SOFT CORAl EXTRACTS MANUFACTURED BY ULTRASONIFICATION METHOD AND FUNCTIONAL COSMETIC COMPOSITION | |
KR20140145666A (en) | Composition comprising natural complex of fucoxanthin, salix babylonica and low molecular weight alginate for preventing or treating of obesity | |
KR20130058388A (en) | Antioxidative composition comprising fermented liriope platyphylla extract as an active ingredient | |
KR102607716B1 (en) | A composition for preventing or improving circadian rhythm disorders comprising Artemisia annua plant extracts or artemisinin | |
KR102515226B1 (en) | Pharmaceutical composition comprising mixing fermentation product of Citrus onshiu and Raphanus sativus | |
KR20120055476A (en) | Composition comprising lespedeza cuneata extract having anti-oxidation activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |